7575-27-1

Upstream product

• 16315-07-4 2,3-dinitroanisole 
• 62-53-3 aniline 
• 67853-37-6 2-bromo-1-methoxy-3-nitrobenzene 
• 108-86-1 bromobenzene 
• 16554-45-3 2-methoxy-6-nitroaniline 

Downstream Products

• 2876-17-7 1-methoxyphenazine 
• 528-71-2 phenazin-1-ol 

Relevant academic research and scientific papers

Design, synthesis and biological evaluations of diverse Michael acceptor-based phenazine hybrid molecules as TrxR1 inhibitors

A series of novel phenazine derivatives (1~27) containing the Michael acceptor scaffolds were designed and synthesized in this study. Some compounds exhibited selective cytotoxicity against Bel-7402 cancer cell line in vitro, in which compound 26 were found to have the best antiproliferative activity. Meanwhile, compound 26 showed no obvious cell toxicity against human normal liver epithelial L02 cells, which means this compound possessed a better safety potential. In the following research, compound 26 was verified to inhibit TrxR1 enzyme activity, ultimately resulting in cellular molecular mechanism events of apoptosis including growth of intracellular ROS level, depletion of reduced Trx1, liberation of ASK1 and up-regulation of p38, respectively. Together, all these evidences implicated that compound 26 acted as the TrxR1 inhibitor against Bel-7402 cells, and could activate apoptosis through the ROS-Trx-ASK1-p38 pathway.

Ionic luminous platinum complex based on benzimidazole phosphine ligand and preparation method of ionic luminous platinum complex

The invention relates to an ionic luminous platinum complex based on a benzimidazole phosphine ligand and a preparation method of the ionic luminous platinum complex, belonging to the technical field of synthesis of organic complexes. The molecular formula of the platinum complex is [C44H31N3PPtS]OTF, [C45H33N3OPPtS]OTF or [C45H30F3N3PPtS]OTF. The ionic luminous platinum complex has strong absorption (wherein epsilon is greater than 5 * 10 L. mol. cm ) at a wavelength of near 230 nm, medium-intensity absorption in a wavelength range of 280-360 nm and low-intensity absorption in a wavelength range of 375-430 nm; the luminous quantum efficiency of the ionic luminous platinum complex in a 293K solution and a solid state is up to 86.6% and 69.1% respectively; and the service life of the ionic luminous platinum complex in the 293K solution and the solid state is up to 6.1 microseconds and 18.9 microseconds respectively. The ionic luminous platinum complex is a high-efficiency OLED photoluminescent material and can be used in the field of preparation of OLED luminescent materials.

Ni-Catalyzed Dual C-H Annulation of Benzimidazoles with Alkynes for Synthesis of π-Extended Heteroarenes

Transition metal catalyzed dual C-H activation and annulation with alkynes was an attractive protocol to construct polycyclic π-extended structures. However, most of them were dominated by noble metal catalysts. Disclosed herein was the study of base-metal Ni-catalysis for dual C-H annulation of N-aromatic imidazole, which produced a range of desired polycyclic aza-quinolines in 48-95% yields. The use of bifunctional phosphine oxide ligand proved to be critical for success.

An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration

Bacterial biofilms are surface-attached communities comprised of nonreplicating persister cells housed within a protective extracellular matrix. Biofilms display tolerance toward conventional antibiotics, occur in ～80% of infections, and lead to >500000 deaths annually. We recently identified halogenated phenazine (HP) analogues which demonstrate biofilm-eradicating activities against priority pathogens; however, the synthesis of phenazines presents limitations. Herein, we report a refined HP synthesis which expedited the identification of improved biofilm-eradicating agents. 1-Methoxyphenazine scaffolds were generated through a Buchwald-Hartwig cross-coupling (70% average yield) and subsequent reductive cyclization (68% average yield), expediting the discovery of potent biofilm-eradicating HPs (e.g., 61: MRSA BAA-1707 MBEC = 4.69 μM). We also developed bacterial-selective prodrugs (reductively activated quinone-alkyloxycarbonyloxymethyl moiety) to afford HP 87, which demonstrated excellent antibacterial and biofilm eradication activities against MRSA BAA-1707 (MIC = 0.15 μM, MBEC = 12.5 μM). Furthermore, active HPs herein exhibit negligible cytotoxic or hemolytic effects, highlighting their potential to target biofilms.

PHENAZINE DERIVATIVES AS ANTIMICROBIAL AGENTS

The present invention provides novel phenazine derivatives, such as compounds of Formula (I) (e.g., Formulae (II) - (XIX)), and pharmaceutically acceptable salts thereof. The compounds of the invention are expected to be antimicrobial agents and may act b